Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease (CKD) is a progressive condition characterized by kidney damage lasting ≥3 months, It currently affects>10% of the general population with an estimated global prevalence of 850 million cases. Health technology assessment (HTA) agencies evaluate the value of interventions through cost-effectiveness analyses, reliant on health state utility values for calculating quality-adjusted life years. Utility values express the preferences of patients over different health states and measure patients’ quality of life (QoL) between 1 (perfect health) and 0 (death), and negative values represent health states worse than death. The current systematic literature review aimed to identify evidence on the utilities in CKD patients.
A comprehensive literature search was performed in Embase®, MEDLINE®, and Cochrane databases to identify relevant articles published on utilities in CKD between 1st January 2004 to 7th August 2024. Additionally key conferences, HTA websites and bibliographic searches were conducted. The quality of included studies was assessed using the National Institute for Health and Care Excellence utility checklist. Publications meeting a pre-defined inclusion criterion, reporting utilities in CKD patients were included.
A total of 67 studies were included in the review. The studies were found to be of moderate quality. Study designs were clinical trials (n=10), or observational studies (n=57) with sample sizes ranging from 15 to 6,262. Mean baseline age of CKD patients ranged from 45.40 to 77.20 years, and the proportion of female patients ranged from 20.90% to 61.80%. The mean utilities in clinical trials and observational studies ranged from 0.63 to 0.76 and 0.38 to 0.91 respectively. Most studies (n=47) used EuroQol-5D (EQ-5D) to assess the utility values. The mean utilities among patients aged <65 years and elderly patients (aged ≥65 years) ranged from 0.52 to 0.98 and 0.38 to 0.89 respectively. There was no difference in mean utilities identified with respect to gender (male: 0.49 to 0.95 vs female: 0.46 to 0.95). A sub-group of patients with comorbidities and disease symptoms showed mean utilities ranging from 0.071 to 0.90 and 0.41 to 0.78 respectively. Whereas mean utilities in patients without comorbidities and symptoms the mean utilities ranged from 0.54 to 0.95 and 0.72 to 0.85 respectively. Studies reported higher utility values among patients who were in the early CKD stages (1-3) vs. patients in the advanced /later CKD stages or dialysis, indicating worsening of health and QoL as the disease progresses (Table 1). Mean utilities of patients undergoing dialysis ranged from 0.026 to 0.77.
Health state utility values in CKD decline progressively as the disease severity increases, with the most significant reductions observed in patients undergoing dialysis. These findings highlight an unmet need in the management of CKD, emphasizing the importance of innovative therapeutic approaches aimed at arresting disease progression and improving the QoL in individuals living with CKD.
